Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Anti-IgE Monoclonal Antibody Injection(Omalizumab) in Patients With Allergic Asthma

NCT01976208 is registered in ClinicalTrials.gov with Shanghai Zhangjiang Biotechnology Limited Company as lead sponsor.

NCT NCT01976208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01976208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Anti-IgE Monoclonal Antibody Injection(Omalizumab) in Patients With Allergic Asthma
Lead sponsor
Shanghai Zhangjiang Biotechnology Limited Company
Phase
Phase 2/3
Overall status
Completed
Start date
December 31, 2010
Completion date
December 31, 2015
Enrollment
630 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

allergic asthma